纳武利尤单抗联合伊匹木单抗对比化疗一线治疗转移性非小细胞肺癌的五年生存结局:CheckMate 227研究
CheckMate 227第1部分5年结果:无论肿瘤PD-L1表达状态,纳武利尤单抗联合伊匹木单抗对比化疗均提高转移性非小细胞肺癌5年总生存率。PD-L1≥1%组5年OS率为24%对14%,PD-L1<1%组为19%对7%。所有患者停用免疫治疗≥3年,未观察到新的安全性信号。
要点
- PD-L1≥1%患者5年OS率:纳武利尤单抗联合伊匹木单抗24%对化疗14%。
- PD-L1<1%患者5年OS率:纳武利尤单抗联合伊匹木单抗19%对化疗7%。
- 因治疗相关不良事件停用联合治疗者5年OS率为39%(合并PD-L1≥1%和<1%人群)。
核心结论
- 所有患者停用免疫治疗≥3年时,纳武利尤单抗联合伊匹木单抗对比化疗提高5年生存率,无论肿瘤PD-L1表达状态均显示长期持久临床获益。
- 这些数据支持纳武利尤单抗联合伊匹木单抗作为转移性非小细胞肺癌的有效一线治疗。
研究设计与样本
- CheckMate 227第1部分5年结果报告。
- 成人IV期/复发性非小细胞肺癌患者,无EGFR突变或ALK改变,肿瘤PD-L1≥1%或<1%,共1739例随机分配。
- 肿瘤PD-L1≥1%患者随机分配至一线纳武利尤单抗联合伊匹木单抗、纳武利尤单抗单药或化疗。
- 肿瘤PD-L1<1%患者随机分配至纳武利尤单抗联合伊匹木单抗、纳武利尤单抗联合化疗或化疗。
- 终点包括疗效、安全性和生活质量的探索性5年结果。
主要发现
- 中位随访至少61.3个月时,PD-L1≥1%患者5年OS率纳武利尤单抗联合伊匹木单抗组24%对化疗组14%。
- PD-L1<1%患者5年OS率纳武利尤单抗联合伊匹木单抗组19%对化疗组7%。
- 中位缓解持续时间PD-L1≥1%患者纳武利尤单抗联合伊匹木单抗组24.5个月对化疗组6.7个月。
- 中位缓解持续时间PD-L1<1%患者纳武利尤单抗联合伊匹木单抗组19.4个月对化疗组4.8个月。
- 5年生存者中,PD-L1≥1%组66%和PD-L1<1%组64%在5年时间点已停用纳武利尤单抗联合伊匹木单抗且未启动后续全身抗肿瘤治疗。
临床怎么用
- 原文结论支持纳武利尤单抗联合伊匹木单抗作为转移性非小细胞肺癌的有效一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic non-small-cell lung cancer, regardless of tumor programmed death ligand 1 (PD-L1) status. METHODS: Adults with stage IV/recurrent non-small-cell lung cancer without EGFR mutations or ALK alterations and with tumor PD-L1 ≥ 1% or < 1% (n = 1739) were randomly assigned. Patients with tumor PD-L1 ≥ 1% were randomly assigned to first-line nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. Patients with tumor PD-L1 < 1% were randomly assigned to nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy. End points included exploratory 5-year results for efficacy, safety, and quality of life. RESULTS: At a minimum follow-up of 61.3 months, 5-year OS rates were 24% versus 14% for nivolumab plus ipilimumab versus chemotherapy (PD-L1 ≥ 1%) and 19% versus 7% (PD-L1 < 1%). The median duration of response was 24.5 versus 6.7 months (PD-L1 ≥ 1%) and 19.4 versus 4.8 months (PD-L1 < 1%). Among patients surviving 5 years, 66% (PD-L1 ≥ 1%) and 64% (PD-L1 < 1%) were off nivolumab plus ipilimumab without initiating subsequent systemic anticancer treatment by the 5-year time point. Survival benefit continued after nivolumab plus ipilimumab discontinuation because of treatment-related adverse events, with a 5-year OS rate of 39% (combined PD-L1 ≥ 1% and < 1% populations). Quality of life in 5-year survivors treated with nivolumab plus ipilimumab was similar to that in the general US population through the 5-year follow-up. No new safety signals were observed. CONCLUSION: With all patients off immunotherapy treatment for ≥ 3 years, nivolumab plus ipilimumab increased 5-year survivorship versus chemotherapy, including long-term, durable clinical benefit regardless of tumor PD-L1 expression. These data support nivolumab plus ipilimumab as an effective first-line treatment for patients with metastatic non-small-cell lung cancer.
引用
- Brahmer JR, Lee JS, Ciuleanu TE, et al. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. J Clin Oncol. 2022. PMID: 36223558. doi:10.1200/JCO.22.01503
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。